search
Back to results

Effectiveness of Bilateral PTNS Compared to Unilateral PTNS for the Treatment of Overactive Bladder/Urge Incontinence (BUTTON)

Primary Purpose

Overactive Bladder Syndrome, Urinary Incontinence, Urge

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
PTNS
Sponsored by
Gnankang Sarah Napoe
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Overactive Bladder Syndrome focused on measuring overactive bladder, OAB, urge urinary incontinence, PTNS

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Female patients over the age of 18 who have previously tried and failed, or were unable to tolerate, behavioral therapy
  2. Patients who consent to participate in the study
  3. Patients on pharmacologic therapy at the time of recruitment can continue their treatment

Exclusion Criteria:

  1. Pregnant patients
  2. Patients with pacemakers of implantable defibrillators
  3. Patients with neurogenic bladder
  4. Patients who have received Botox or have an implant for sacral nerve stimulation
  5. Patients with uncontrolled bleeding disorder
  6. Patients with unhealed ulcers or with leg edema surrounding medial malleolus

Sites / Locations

  • Gnankang Sarah NapoeRecruiting
  • WIHRI

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Unilateral PTNS

Bilateral PTNS

Arm Description

34 gauge needle inserted 3cm above the medial ankle on the ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period

34 gauge needle inserted 3cm above the medial ankle on both ankles, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period

Outcomes

Primary Outcome Measures

Change in OAB symptom severity score
Overactive Bladder questionnaire short form symptom severity will be administered at baseline, 4 weeks, 8 weeks then 12 weeks. The questionnaire score ranges from 0 to 100. Those with more bothersome symptoms will have higher scores. The investigators expect more improvement in symptoms from participants receiving bilateral stimulation compared to those with unilateral stimulation.

Secondary Outcome Measures

Change in daily number of voids
Number of voids at baseline will be compared to the number of voids after completion of PTNS at 12 weeks
Change in number of incontinence episodes per 24 hours
The number of incontinence episodes will be calculated from the voiding diary
Change in nocturia episodes
A bladder diary will be used to determine how many episodes of voiding occurs at night (nocturia). Baseline nocturia will be compared to nocturia at 12 weeks
Evaluate impact of treatment on quality of life
The incontinence impact questionnaire will be used to measure impact on qualify of life. The questionnaire score range from 0 to 100 with higher scores indicating worse quality of life.

Full Information

First Posted
May 8, 2018
Last Updated
February 7, 2023
Sponsor
Gnankang Sarah Napoe
search

1. Study Identification

Unique Protocol Identification Number
NCT03535857
Brief Title
Effectiveness of Bilateral PTNS Compared to Unilateral PTNS for the Treatment of Overactive Bladder/Urge Incontinence
Acronym
BUTTON
Official Title
Effectiveness of Bilateral PTNS Compared to Unilateral PTNS for the Treatment of Overactive Bladder/Urge Incontinence
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 17, 2018 (Actual)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
December 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Gnankang Sarah Napoe

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is designed to evaluate whether bilateral Posterior Tibial Nerve Stimulation is more effective than unilateral Posterior Tibial Nerve Stimulation at treating overactive bladder and urge urinary incontinence
Detailed Description
Percutaneous tibial nerve stimulation (PTNS) is an accepted treatment for overactive bladder that can be accomplished in the office with minimal side effects. It is currently carried out by stimulating one of the posterior tibial nerves unilaterally. The aim of this study is to determine whether bilateral percutaneous tibial nerve stimulation is more effective than unilateral stimulation. Patients with a diagnosis of overactive bladder who have previously failed lifestyle changes and/or pharmacologic therapy will be offered percutaneous tibial nerve stimulation. Enrolled patients will be randomized into two groups. The control group will receive the traditional unilateral treatment of PTNS. The intervention group will receive bilateral PTNS treatment. Intervention success will be measured by improvement in overactive bladder symptoms assessed by improvement in the scores on the overactive bladder questionnaire symptoms bother and decrease in number of voids, nocturia episodes and incontinence episodes as reported in the voiding diary

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overactive Bladder Syndrome, Urinary Incontinence, Urge
Keywords
overactive bladder, OAB, urge urinary incontinence, PTNS

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Unilateral PTNS
Arm Type
Active Comparator
Arm Description
34 gauge needle inserted 3cm above the medial ankle on the ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
Arm Title
Bilateral PTNS
Arm Type
Experimental
Arm Description
34 gauge needle inserted 3cm above the medial ankle on both ankles, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
Intervention Type
Device
Intervention Name(s)
PTNS
Intervention Description
Use of PTNS on the ankle for 30 minutes
Primary Outcome Measure Information:
Title
Change in OAB symptom severity score
Description
Overactive Bladder questionnaire short form symptom severity will be administered at baseline, 4 weeks, 8 weeks then 12 weeks. The questionnaire score ranges from 0 to 100. Those with more bothersome symptoms will have higher scores. The investigators expect more improvement in symptoms from participants receiving bilateral stimulation compared to those with unilateral stimulation.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Change in daily number of voids
Description
Number of voids at baseline will be compared to the number of voids after completion of PTNS at 12 weeks
Time Frame
12 weeks
Title
Change in number of incontinence episodes per 24 hours
Description
The number of incontinence episodes will be calculated from the voiding diary
Time Frame
12 weeks
Title
Change in nocturia episodes
Description
A bladder diary will be used to determine how many episodes of voiding occurs at night (nocturia). Baseline nocturia will be compared to nocturia at 12 weeks
Time Frame
12 weeks
Title
Evaluate impact of treatment on quality of life
Description
The incontinence impact questionnaire will be used to measure impact on qualify of life. The questionnaire score range from 0 to 100 with higher scores indicating worse quality of life.
Time Frame
12 weeks

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female patients over the age of 18 who have previously tried and failed, or were unable to tolerate, behavioral therapy Patients who consent to participate in the study Patients on pharmacologic therapy at the time of recruitment can continue their treatment Exclusion Criteria: Pregnant patients Patients with pacemakers of implantable defibrillators Patients with neurogenic bladder Patients who have received Botox or have an implant for sacral nerve stimulation Patients with uncontrolled bleeding disorder Patients with unhealed ulcers or with leg edema surrounding medial malleolus
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
G. Sarah Napoe, MD
Phone
412-641-7850
Email
napoegs@upmc.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Ann Meers
Phone
401-453-7560
Email
ameers@wihri.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
G. Sarah Napoe, MD
Organizational Affiliation
University of Pittsburgh
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kyle Wohlrab, MD
Organizational Affiliation
Women and Infants Hospital of Rhode Island
Official's Role
Principal Investigator
Facility Information:
Facility Name
Gnankang Sarah Napoe
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15203
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
G. Sarah Napoe, MD
Phone
412-641-7850
Email
napoegs@upmc.edu
First Name & Middle Initial & Last Name & Degree
Judy Gruss
Phone
412-641-7850
Email
jgruss@upmc.edu
Facility Name
WIHRI
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02905
Country
United States
Individual Site Status
Active, not recruiting

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
No plan to share IPD

Learn more about this trial

Effectiveness of Bilateral PTNS Compared to Unilateral PTNS for the Treatment of Overactive Bladder/Urge Incontinence

We'll reach out to this number within 24 hrs